Objectives Resistance to all β-lactams is emerging among Pseudomonas aeruginosa (PA)
clinical isolates. Aztreonam and cefepime act synergistically in vitro against AmpC …

Bacterial resistance, the medical challenge of the next 20 years. - Abstract - Europe PMC
Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …

Objective: The emergence of Pseudomonas aeruginosa resistance to antimicrobial drugs is
frequent in intensive care units and may be correlated with the use of some specific drugs …

Objective To assess the role of antipseudomonal agents on Pseudomonas aeruginosa
colonization and acquisition of resistance. Design Prospective cohort study. Setting Two …

Background Pseudomonas aeruginosa remains an important cause of hospital-acquired
infections in the United States and is frequently multidrug-resistant (MDR). The Infectious …

Pseudomonas aeruginosa, a frequent pathogen in the intensive care unit (ICU), has the
propensity to develop antibiotic resistance. In particular, carbapenem-nonsusceptible (NS) …

Background Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor
combination that often retains activity against resistant Pseudomonas aeruginosa. The …

Abstract Study Objectives The most commonly prescribed antibiotics for patients with
hospital‐acquired bacterial pneumonia (HABP) and ventilator‐associated bacterial …

Pseudomonas aeruginosa is an important opportunistic pathogen commonly associated
with nosocomial infections occurring in intensive care units (ICUs). Drug resistance of P …

Ceftolozane-tazobactam (CT) and ceftazidime-avibactam (CAZ-AVI) are two novel
antimicrobials that retain activity against resistant Pseudomonas aeruginosa. The …